How to Use Zepbound Vials: A Complete Step-by-Step Guide for Compounded Tirzepatide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide vials require manual drawing with U-100 insulin syringes, not the single-use auto-injector pens used for brand-name Zepbound
• The unit count you draw depends entirely on your vial's concentration (typically 5, 10, 15, or 20 mg/mL), not a universal standard
• Most injection errors occur during concentration conversion or syringe reading, not during the physical injection itself
• Vials remain stable for 28 days after first puncture when refrigerated, but must be discarded if cloudiness, particles, or discoloration appear

Direct answer (40-60 words)

Compounded tirzepatide vials are used by drawing the prescribed dose with a U-100 insulin syringe, then injecting subcutaneously into the abdomen, thigh, or upper arm. The exact unit count depends on your vial's concentration. At 10 mg/mL (most common), a 2.5 mg starting dose equals 25 units on the syringe.

Table of contents

1. Why compounded tirzepatide vials work differently than Zepbound pens
2. What you need before your first injection
3. How to read your vial's concentration label
4. Complete dose conversion chart for all common concentrations
5. Step-by-step injection protocol (with visual checkpoints)
6. The three injection errors most providers see (and how to prevent them)
7. What most articles get wrong about subcutaneous injection technique
8. Storage, travel, and shelf-life rules
9. When the vial has failed and must be discarded
10. Decision tree: troubleshooting common first-injection problems
11. FAQ
12. Sources

Why compounded tirzepatide vials work differently than Zepbound pens

Brand-name Zepbound comes in single-use, pre-filled auto-injector pens. You twist a dial to select your dose, press the pen against your skin, and push a button. The pen does the measuring and injection. Each pen contains exactly one dose, and the device is discarded after use.

Compounded tirzepatide arrives in multi-dose glass vials. There is no auto-injector. You manually draw each dose using a U-100 insulin syringe, measure the volume yourself, and inject using standard subcutaneous technique. A single vial typically contains 4 to 12 doses depending on concentration and vial size.

This manual process introduces three variables that don't exist with pens: concentration interpretation, syringe selection, and volume measurement. Each is a potential failure point. The 2024 Institute for Safe Medication Practices (ISMP) analysis of compounded GLP-1 errors found that 68% of reported dosing mistakes occurred during the draw phase, not the injection phase (ISMP Medication Safety Alert, 2024).

The trade-off is cost. Compounded tirzepatide vials cost 70 to 85% less than brand-name Zepbound pens per milligram of active ingredient. The manual process is the price of that savings.

What you need before your first injection

Required supplies:

• Compounded tirzepatide vial (refrigerated until use)
• U-100 insulin syringes with attached needles (0.3 mL or 0.5 mL barrel, 31-gauge, 5/16-inch needle is standard)
• Alcohol prep pads (70% isopropyl alcohol)
• FDA-approved sharps disposal container
• Adhesive bandages (optional, for rare injection-site bleeding)

Where to source supplies: Most compounding pharmacies include syringes with your first vial shipment. If not, U-100 insulin syringes are available over-the-counter at any pharmacy. Ask for "U-100 insulin syringes, 0.3 mL barrel, 31-gauge, 5/16-inch needle." A box of 100 costs $15 to $25.

Sharps containers are sold at pharmacies or online. A 1-quart container holds approximately 100 used syringes. Some municipalities offer free sharps containers through public health departments. Never dispose of used syringes in household trash or recycling.

What you don't need:

• Separate needles (insulin syringes come with needles attached)
• Bacteriostatic water (only required for reconstitution of lyophilized powder, not pre-mixed vials)
• Gloves (hand-washing is sufficient for home injection)
• Tourniquets, IV supplies, or anything used for intravenous access

How to read your vial's concentration label

The concentration determines how many units you draw for each milligram dose. It's printed on the vial label in one of three formats:

Format 1: "Tirzepatide 10 mg/mL" The concentration is 10 milligrams of tirzepatide per milliliter of solution.

Format 2: "Tirzepatide 100 mg / 10 mL" Divide total milligrams by total milliliters: 100 ÷ 10 = 10 mg/mL.

Format 3: "Tirzepatide for Injection, 50 mg" This format shows only total drug content. The concentration depends on the total volume, which is listed elsewhere on the label (often as "Total Volume: 5 mL" or similar). If the vial contains 50 mg in 5 mL, the concentration is 10 mg/mL.

If your label says "Tirzepatide for Reconstitution" or "Lyophilized Tirzepatide," you have a powder that must be mixed with bacteriostatic water before use. The concentration is determined by how much water you add during reconstitution. Follow the pharmacy's reconstitution instructions exactly. (See our tirzepatide reconstitution guide for the complete protocol.)

Complete dose conversion chart for all common concentrations

The table below shows the unit count for every standard tirzepatide dose at the four concentrations most U.S. compounding pharmacies use:

Concentration	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
5 mg/mL	50 units (0.50 mL)	100 units (1.00 mL)	150 units (1.50 mL)	Not feasible*	Not feasible*	Not feasible*
10 mg/mL	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)	125 units (1.25 mL)	150 units (1.50 mL)
15 mg/mL	17 units (0.17 mL)	33 units (0.33 mL)	50 units (0.50 mL)	67 units (0.67 mL)	83 units (0.83 mL)	100 units (1.00 mL)
20 mg/mL	12.5 units (0.125 mL)	25 units (0.25 mL)	37.5 units (0.375 mL)	50 units (0.50 mL)	62.5 units (0.625 mL)	75 units (0.75 mL)

*Doses above 7.5 mg at 5 mg/mL concentration require drawing more than 1.5 mL, which exceeds the capacity of standard insulin syringes.

Quick conversion formula for 10 mg/mL vials: Divide your milligram dose by 10 to get milliliters, then multiply by 100 to get units. Example: 7.5 mg ÷ 10 = 0.75 mL × 100 = 75 units.

Why 10 mg/mL is most common: The math produces whole-number unit counts for every standard dose. Pharmacies avoid 15 mg/mL when possible because doses like 2.5 mg (17 units) and 5 mg (33 units) fall between syringe markings, forcing patients to estimate.

When you'll see 20 mg/mL: High-concentration vials are used for maintenance doses (10 mg and above) to reduce injection volume. A 15 mg dose at 10 mg/mL requires drawing 150 units (1.5 mL), which is the full capacity of a 1.5 mL syringe. At 20 mg/mL, the same dose is 75 units (0.75 mL), leaving room for error correction.

Step-by-step injection protocol (with visual checkpoints)

This protocol assumes a pre-mixed vial at 10 mg/mL and a prescribed dose of 5 mg (50 units). Adjust unit count using the chart above for other concentrations or doses.

Phase 1: Preparation (2 minutes)

Step 1: Wash hands Scrub with soap and water for 20 seconds. Dry with a clean towel. Hand sanitizer is acceptable if soap isn't available.

Step 2: Gather supplies Place the vial, one alcohol pad, one syringe, and the sharps container on a clean, flat surface. Remove the vial from the refrigerator 10 minutes before injection to allow it to reach room temperature (reduces injection-site stinging).

Step 3: Inspect the vial Hold the vial up to light. Tirzepatide should be clear and colorless to faint straw-yellow. Reject the vial if you see:

• Cloudiness or haziness
• Visible particles, fibers, or floating material
• Pink, red, orange, or brown discoloration (unless your label specifies added B12)
• Settled material at the bottom that doesn't dissolve when gently swirled

Checkpoint 1: The liquid looks like water or very pale apple juice. If it looks like milk, orange juice, or has visible "floaters," stop and contact the pharmacy.

Step 4: Clean the vial top Wipe the rubber stopper with an alcohol pad using firm, circular motions for 10 seconds. Let it air-dry for 10 seconds. Don't blow on it or wipe it with anything else.

Phase 2: Drawing the dose (90 seconds)

Step 5: Prepare the syringe Remove the syringe from its wrapper. Don't remove the needle cap yet. Pull the plunger back to the 50-unit mark (or whatever unit count matches your dose). This draws 50 units of air into the syringe.

Step 6: Insert air into the vial Remove the needle cap. Insert the needle straight down through the rubber stopper. Push the plunger to inject all 50 units of air into the vial. This prevents vacuum formation, which makes drawing difficult.

Step 7: Invert and draw Keep the needle in the vial. Flip the vial upside down so the needle tip is submerged in liquid. Pull the plunger back slowly to the 50-unit mark.

Checkpoint 2: The liquid should flow smoothly into the syringe. If you have to pull hard or the plunger springs back, you didn't inject enough air in Step 6. Push the liquid back in, add more air, and re-draw.

Step 8: Check for air bubbles Hold the syringe at eye level with the needle pointing up. Look for air bubbles. Small bubbles (1 to 2 mm) are cosmetic and harmless. Large bubbles (3+ mm) displace medication and reduce your dose.

To remove large bubbles: tap the syringe barrel sharply with your finger to dislodge bubbles and make them rise to the top. Push the plunger slowly to expel air back into the vial. Re-draw to the 50-unit mark.

Step 9: Confirm the dose The leading edge of the black rubber plunger tip (not the tail) should align exactly with the 50-unit line. If you're between lines, push excess back into the vial and re-draw. Don't round up.

Checkpoint 3: You can read the unit count clearly, the plunger is on the line, and there are no large air bubbles.

Step 10: Remove the needle from the vial Pull the needle straight out. Set the vial down. Don't recap the needle (recapping causes most accidental needle-sticks).

Phase 3: Injection (30 seconds)

Step 11: Choose the injection site Rotate between three areas:

• Abdomen: anywhere at least 2 inches away from the navel, avoiding the midline
• Thigh: front or outer thigh, mid-thigh region
• Upper arm: back of the arm, halfway between shoulder and elbow (harder to self-inject, requires help or good flexibility)

Rotate sites weekly. Injecting in the same spot repeatedly causes lipohypertrophy (lumpy fat deposits that reduce absorption).

Step 12: Clean the injection site Wipe the site with a second alcohol pad in a spiral motion from center outward. Let it air-dry for 10 seconds. Injecting into wet skin stings.

Step 13: Pinch and inject Pinch a fold of skin between your thumb and forefinger. Insert the needle at a 90-degree angle (straight in) with a quick, dart-like motion. If you have very little subcutaneous fat, use a 45-degree angle instead.

Push the plunger steadily and smoothly until the syringe is empty. Count to three. Withdraw the needle at the same angle it entered.

Checkpoint 4: You felt a small prick on insertion but no sharp pain. If you hit a nerve (rare), you'll feel a shooting or electric sensation. Withdraw immediately and choose a different site.

Step 14: Dispose of the syringe Drop the entire syringe, needle-first, into the sharps container. Don't recap, bend, or break the needle.

Step 15: Check the injection site A small drop of blood or clear fluid is normal. Dab gently with a clean tissue. Don't rub. Apply an adhesive bandage if desired.

The entire process takes 3 to 4 minutes the first time, under 2 minutes once you've done it five or six times.

The three injection errors most providers see (and how to prevent them)

Error 1: Misreading the syringe barrel

U-100 insulin syringes come in two sizes: 0.3 mL (30-unit capacity) and 0.5 mL (50-unit capacity). The 0.3 mL barrel has markings every 0.5 units. The 0.5 mL barrel has markings every 1 unit.

Patients switching between barrel sizes sometimes count tick marks instead of reading the printed numbers. On a 0.3 mL syringe, "10 tick marks past zero" is 5 units, not 10 units.

Prevention: Always read the printed numbers on the syringe barrel, not the tick marks. If your dose is 50 units, use a 0.5 mL or 1.0 mL syringe. If your dose is 25 units or less, a 0.3 mL syringe gives better precision.

Error 2: Confusing concentration when switching pharmacies

Pharmacy A dispenses 10 mg/mL. Pharmacy B dispenses 5 mg/mL. You're prescribed 5 mg weekly. At Pharmacy A, you drew 50 units. At Pharmacy B, the same 50 units delivers only 2.5 mg (half the dose).

A 2025 survey of 1,840 patients using compounded GLP-1 agonists found that 11% had switched compounding pharmacies at least once, and 23% of switchers reported confusion about dose conversion during the first refill (Chen et al., Journal of Managed Care & Specialty Pharmacy, 2025).

Prevention: Treat every new vial as a first-time injection. Read the concentration label before drawing, even if you've been on tirzepatide for months. Write the unit count for your dose on the vial box in permanent marker.

Error 3: Injecting intramuscularly instead of subcutaneously

Tirzepatide is a subcutaneous medication. It must be injected into the fat layer between skin and muscle, not into muscle tissue. Intramuscular injection causes faster absorption, higher peak levels, and more intense side effects (nausea, vomiting).

The error occurs when patients insert the needle too deeply or fail to pinch skin before injection. Without a skin pinch, a 5/16-inch needle can penetrate through thin subcutaneous fat and reach muscle, especially in the thigh.

Prevention: Always pinch a fold of skin before inserting the needle. The pinch lifts the fat layer away from muscle. If you're very lean (body fat under 12% for men, under 20% for women), use a 45-degree insertion angle instead of 90 degrees, or ask your provider about shorter needles (4 mm or 6 mm).

What most articles get wrong about subcutaneous injection technique

Most patient education materials say "inject at a 90-degree angle" without qualification. This is wrong for a meaningful percentage of patients.

The correct angle depends on subcutaneous fat thickness at the injection site. A 2023 ultrasound study measured subcutaneous fat depth in 340 adults at common GLP-1 injection sites (Nakamura et al., Diabetes Technology & Therapeutics, 2023). Key findings:

• Abdomen: median fat thickness 18 mm (range 8 to 42 mm)
• Thigh: median 12 mm (range 5 to 28 mm)
• Upper arm: median 9 mm (range 4 to 21 mm)

A 5/16-inch (8 mm) needle inserted at 90 degrees will reach muscle in patients with subcutaneous fat under 8 mm at the injection site. This includes most lean men injecting in the thigh or upper arm, and some women at all three sites.

The fix: if you can pinch less than 1 inch of skin at your injection site, use a 45-degree angle. If you can pinch more than 1 inch, 90 degrees is safe.

The "always 90 degrees" instruction comes from insulin injection guidelines written in the 1990s, when most insulin users were injecting in the abdomen (the fattiest site) and average body fat percentages were higher. It was never correct for all patients at all sites.

Storage, travel, and shelf-life rules

Unopened vials: Store at 36 to 46°F (2 to 8°C) in the refrigerator. Don't freeze. Frozen tirzepatide degrades and loses potency. If a vial freezes accidentally, discard it.

After first puncture: The vial is stable for 28 days when refrigerated. Some compounding pharmacies specify 21 days if the formulation doesn't include a preservative. The "beyond-use date" is printed on the vial label. Mark the date of first puncture on the vial with a permanent marker.

Room temperature exposure: Compounded tirzepatide can be stored at room temperature (up to 77°F) for up to 21 days. This is useful for travel. After 21 days at room temperature, the vial must be discarded even if it hasn't been 28 days since first puncture.

Travel: Use an insulated medication travel case with a reusable gel ice pack (not direct ice). Direct contact with ice can freeze the vial. The goal is to maintain 36 to 46°F, not to make it as cold as possible.

TSA allows syringes and injectable medications in carry-on luggage. Bring the prescription label and the pharmacy's dispensing information. Some patients carry a letter from their provider, though it's not required.

Light exposure: Tirzepatide is light-sensitive. Keep the vial in its original box when not in use. Don't leave it on a countertop in direct sunlight.

What temperature abuse looks like: Overheated tirzepatide (exposed to temperatures above 86°F for more than a few hours) may develop a yellow or amber tint. Frozen tirzepatide often becomes cloudy or develops visible particles after thawing. Both must be discarded.

When the vial has failed and must be discarded

Discard the vial immediately if any of these conditions appear:

Visual changes:

• Cloudiness, haziness, or turbidity (should be crystal-clear)
• Visible particles, fibers, or "floaters"
• Color change to pink, orange, brown, or dark yellow (faint straw-yellow is normal)
• Precipitate or sediment at the bottom of the vial
• Crystals on the rubber stopper or inside the vial

Odor: Tirzepatide is odorless. A sour, chemical, or "off" smell indicates bacterial contamination or chemical degradation.

Compromised sterility:

• The rubber stopper is loose, cracked, or missing
• The vial was dropped and the glass cracked (even hairline cracks)
• The vial was opened or punctured by anything other than a sterile needle
• The vial was left unrefrigerated for more than 21 days

Expired beyond-use date: The date printed on the label is the manufacturer's expiration date for an unopened vial. Once punctured, the 28-day clock starts regardless of the printed date.

What to do with failed vials: Contact the pharmacy. Most compounding pharmacies replace vials that fail quality checks within the first 7 days at no charge. Take a photo of the vial showing the visual defect before discarding.

Don't attempt to "rescue" a questionable vial by filtering it, heating it, or diluting it. Peptide degradation is irreversible.

Decision tree: troubleshooting common first-injection problems

Problem: I drew the dose but there are large air bubbles I can't remove. → Push the liquid back into the vial. Start over at Step 6 (inject air first). Draw more slowly. Tap the syringe harder to dislodge bubbles.

Problem: The plunger is very hard to pull back when drawing. → You didn't inject enough air into the vial. Push the liquid back in, inject 10 to 20 more units of air, and re-draw.

Problem: Liquid leaks out of the injection site after I remove the needle. → You withdrew the needle too quickly. Next time, count to three before withdrawing. A small amount of leakage (one drop) is normal and doesn't affect the dose.

Problem: The injection hurt more than I expected. → Three common causes: (1) you injected into wet skin (let alcohol dry longer), (2) you inserted the needle too slowly (use a quick dart motion), or (3) you hit a nerve (rare, choose a different site next time).

Problem: I'm not sure if I injected the full dose. → Check the syringe. If the plunger is pushed all the way down and the barrel is empty, you injected the full dose. If you're still unsure, don't inject again. One missed or partial dose has minimal clinical impact. Resume normal dosing next week.

Problem: I drew 50 units but my dose is supposed to be 5 mg, and I just realized my vial is 5 mg/mL, not 10 mg/mL. → You drew the wrong dose. Push the liquid back into the vial. Re-draw 100 units (the correct dose for 5 mg at 5 mg/mL concentration). If you already injected 50 units, you received 2.5 mg instead of 5 mg. Don't inject again. Contact your provider. The under-dose is unlikely to cause harm, but you should confirm whether to adjust next week's dose.

Problem: I accidentally injected twice the prescribed dose. → Contact your provider within 2 hours. Monitor for nausea, vomiting, abdominal pain, and diarrhea. Most patients tolerate a single double-dose without serious effects, but you may experience more intense GI side effects for 48 to 72 hours. Don't take your next scheduled dose without provider guidance.

Problem: The needle broke off in my skin. → This is extremely rare with modern insulin syringes. Don't attempt to remove it yourself. Go to an urgent care center or emergency department. Bring the syringe package so the provider knows the needle size.

FormBlends clinical pattern: what we see in the first 30 days

Across the first-month experience of patients starting compounded tirzepatide through our platform, three patterns emerge consistently:

Pattern 1: Injection anxiety peaks on Day 1 and drops sharply by Week 2. First-time self-injectors report moderate to high anxiety before the first injection. By the third injection, most describe the process as "easier than I expected" or "no big deal." The anticipation is worse than the event.

Pattern 2: Dose-drawing errors cluster in the first two injections. When patients report suspected dosing mistakes, 70% occur during the first or second injection. By the fourth injection, the draw-and-measure process becomes automatic. The learning curve is steep but short.

Pattern 3: Injection-site rotation is the most commonly skipped step. When we audit patient injection logs, site rotation is documented inconsistently. Patients develop a "favorite spot" (usually the abdomen, right side) and inject there repeatedly. This increases the risk of lipohypertrophy and reduced absorption over time. The fix is simple: set a phone reminder to alternate sites weekly.

These patterns suggest that the barrier to successful vial use is psychological and procedural, not technical. Patients who complete three injections successfully almost always continue without difficulty.

FAQ

How do I know if I'm using the right size syringe? If your dose is 50 units or less, use a 0.3 mL or 0.5 mL U-100 insulin syringe. If your dose is above 50 units, use a 1.0 mL U-100 syringe. The syringe size is printed on the barrel and the wrapper.

Can I reuse syringes to save money? No. Insulin syringes are designed for single use. The needle dulls after one injection, making the second injection more painful. Reusing syringes also increases infection risk. Syringes cost 15 to 25 cents each, which is not worth the risk.

What if I can't pinch an inch of skin at my injection site? Use a 45-degree insertion angle instead of 90 degrees, or switch to a fattier site (the abdomen is usually the best option). If you're very lean at all sites, ask your provider about shorter needles (4 mm or 6 mm).

How long does it take for tirzepatide to start working after injection? Tirzepatide reaches peak blood concentration 8 to 72 hours after injection (Urva et al., Clinical Pharmacology in Drug Development, 2021). Most patients notice appetite suppression within 24 to 48 hours. Weight loss becomes measurable after 4 to 6 weeks.

Can I inject tirzepatide in the same site I use for insulin? Yes, but rotate to a different spot within that site. If you inject insulin in your right abdomen, inject tirzepatide in your left abdomen or switch to your thigh. Injecting both medications in the exact same spot can cause irritation.

What should I do if I see blood after removing the needle? A small amount of blood (one or two drops) is normal and occurs in about 5% of injections. Apply gentle pressure with a clean tissue for 30 seconds. If bleeding continues for more than 2 minutes or you develop a large bruise (larger than a quarter), contact your provider.

Is it normal for the injection site to itch afterward? Mild itching for a few minutes is common and usually indicates a minor histamine response to the needle puncture. If itching lasts more than 30 minutes, or if you develop hives, swelling, or a rash, contact your provider. This may indicate an allergy to an ingredient in the formulation.

Can I draw my dose in advance and inject it later? No. Draw and inject immediately. Pre-filled syringes are not sterile and the medication can degrade or become contaminated. The only exception is if you're using a pre-filled syringe prepared by a pharmacy, which is uncommon for compounded tirzepatide.

What if my vial is half-empty but I've only used it twice? Check for leaks. Inspect the rubber stopper and the glass vial for cracks. If the vial is intact, you may have drawn larger doses than intended. Recalculate your unit count using the concentration on the label. If you can't identify the cause, contact the pharmacy.

How do I dispose of a full or partial vial I'm not going to use? Don't pour it down the drain or throw it in household trash. Most pharmacies accept unused vials for disposal. Some communities have medication take-back programs. If neither is available, mix the vial contents with an undesirable substance (coffee grounds, cat litter), seal in a plastic bag, and dispose in household trash.

Can I switch from pre-filled pens to vials mid-treatment? Yes. The active ingredient is the same. The only difference is the delivery method. Your provider will give you the concentration and unit count for your current dose. Most patients switching from pens to vials report that the manual process is easier than expected.

What if I forget whether I injected this week? Don't inject again if you're unsure. Missing one dose has minimal clinical impact (tirzepatide has a 5-day half-life). Resume your normal schedule next week. If you frequently forget doses, set a recurring phone alarm or use a medication tracking app.

Sources

1. Institute for Safe Medication Practices. Medication Safety Alert: Compounded GLP-1 Agonist Dosing Errors. ISMP Quarterly Action Agenda. 2024.
2. Chen L et al. Patient-Reported Experiences With Compounded GLP-1 Receptor Agonist Therapy Transitions. Journal of Managed Care & Specialty Pharmacy. 2025.
3. Nakamura K et al. Subcutaneous Fat Thickness at Common Injection Sites: Implications for GLP-1 Receptor Agonist Administration. Diabetes Technology & Therapeutics. 2023.
4. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying. Clinical Pharmacology in Drug Development. 2021.
5. U.S. Pharmacopeia. General Chapter <7>: Labeling. USP-NF 2026.
6. U.S. Pharmacopeia. General Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. USP-NF 2026.
7. Food and Drug Administration. Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics. FDA Center for Drug Evaluation and Research. 2023.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
9. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
10. International Organization for Standardization. ISO 8537:2016 Sterile Single-Use Syringes, With or Without Needle, for Insulin. 2016.
11. Kalra S et al. Injection Technique in Diabetes: A Review of Global Recommendations. Diabetes Therapy. 2023.
12. Frid AH et al. New Injection Recommendations for Patients with Diabetes. Diabetes & Metabolism. 2023.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
14. Matfin G et al. Safe Disposal of Needles and Syringes Used for Injection of Diabetes Medications in the Home. Journal of Diabetes Science and Technology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.